Thymosin alpha-1 regulatory status
Current status of Thymosin alpha-1 in the United States: Nomination withdrawn. In sport: WADA status unclear. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Thymosin alpha-1?
- FDA and compounding
- Not FDA approved, although approved as Zadaxin (thymalfasin) in more than 30 countries. FDA placed thymosin alpha-1 in 503A Category 2 in 2023, citing immunogenicity risk and inadequate safety information for compounded product. FDA's Category 2 page (current as of April 22, 2026) now lists it under bulk drug substances nominated but withdrawn, so it is no longer in Category 2 but has no active nomination and is not on the 503A bulks list. That leaves US compounding pharmacies without a lawful basis to make it. It was not among the peptides reviewed by the advisory committee in July 2026.
- WADA
- WADA status unclear
- Access path
- No lawful United States access path identified on the last verified date; the 503A nomination was withdrawn and it is not on the bulks list.
- Not available as an FDA approved product in the United States, although approved abroad as Zadaxin (thymalfasin).
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Full Thymosin alpha-1 page: evidence, dosing in the literature, and sources
How has the status of Thymosin alpha-1 changed over time?
- FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
- FDA
FDA places a batch of nominated peptides in 503A Category 2
In September 2023 FDA updated its 503A bulk drug substances category lists to place a group of nominated peptides in Category 2, which means FDA identified significant safety risks and the substances may not be used in 503A compounding while the evaluation continues. Kisspeptin-10 and ibutamoren (MK-677) were added on September 29, 2023 and remain in Category 2 on the FDA page current as of April 22, 2026. BPC-157, CJC-1295, ipamorelin, AOD-9604, dihexa, DSIP, epitalon, KPV, MOTS-c, selank, semax, melanotan II, LL-37, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) were also placed in Category 2 under the 503A interim policy; that same page now lists them as nominated but withdrawn (see the April 2026 event). Hexarelin, PNC-27, and 5-amino-1MQ have never appeared on the FDA category lists.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Thymosin alpha-1 and the source of each dated event.
- [1]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA, 2026
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
- [3]FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, DSIP, semax, epitalon)FDA, 2026
- [4]WADA Prohibited ListWADA, 2026
- [5]FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026FDA, 2026
- [6]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
From the blog
- Thymosin alpha-1 benefits and side effects: the evidence
What randomized trials of thymosin alpha-1 showed in hepatitis B, sepsis, COVID-19, and vaccine response, which side effects they recorded, and where wellness claims outrun the data.
- Thymosin alpha-1 access: approved abroad, not in the US
Thymosin alpha-1 is approved as Zadaxin in more than 30 countries but has never been FDA approved, and it is not on the 503A bulks list. What that means for access, forms, and thymalin.